Gossamer Bio
GOSS

$0.9100

0.52%

Market Cap: $206M

About: Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Employees: 135

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

10% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 29

3% more call options, than puts

Call options by funds: $591K | Put options by funds: $576K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

8.48% less ownership

Funds ownership: 89.61% [Q1] → 81.13% (-8.48%) [Q2]

14% less funds holding

Funds holding: 109 [Q1] → 94 (-15) [Q2]

31% less capital invested

Capital invested by funds: $239M [Q1] → $165M (-$73.3M) [Q2]

58% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 26

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$4

340%

upside

Avg. target

$7.75

752%

upside

High target

$10

999%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 40 / 135 met price target	999%upside $10	Buy Reiterated	30 Aug 2024
Wedbush Laura Chico 44% 1-year accuracy 33 / 75 met price target	340%upside $4	Outperform Reiterated	13 Aug 2024
Oppenheimer Andreas Argyrides 59% 1-year accuracy 24 / 41 met price target	889%upside $9	Outperform Initiated	25 Jun 2024
Goldman Sachs Paul Choi 40% 1-year accuracy 4 / 10 met price target	779%upside $8	Buy Maintained	17 Jun 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about GOSS published over the past 30 days

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced two oral presentations and a poster presentation with data relevant to seralutinib at the European Respiratory Society (ERS) Congress 2024, which takes place from September 7t.

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024.

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Zacks Investment Research

Gossamer Bio (GOSS) Q2 Earnings and Revenues Lag Estimates

Gossamer Bio (GOSS) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to loss of $0.45 per share a year ago.

Gossamer Bio (GOSS) Q2 Earnings and Revenues Lag Estimates

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the second quarter ended June 30, 2024 and provided a business update. “Between the continued progress made in the enrollment of the Phase 3 PROSERA.

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

Oppenheimer initiated coverage on Gossamer Bio Inc GOSS, a clinical-stage biopharmaceutical company, with an Outperform rating and a price target of $9.

The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street

Do you have any penny stocks in your portfolio? If you don't, you might want to consider it with any speculative money sitting on the sidelines.

The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective June 5, 2024, to one new non-executive employee of non-qualified stock option aw.

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present updated seralutinib TORREY open-label extension data at the American Thoracic Society 2024 International Conference, which takes place May 17-22 in San Diego, California. Details.

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective May 8, 2024, to three new non-executive employees of non-qualified stock option.

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 31, 2024, and provided a business update. “Our team at Gossamer continues to execute on our mission to enhance the live.

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

See News Rankings